抗体療法のような免疫療法の領域での勝利は、多重特異性抗体の将来を予感させました。その1つが四重特異性アプローチです。四重特異性抗体は標的よりも結合する能力があるため、このクラスの多重特異性抗体は、4つの標的を近接させるという用途において実用的な利点がありました。したがって、四重特異性抗体の潜在能力を活用することにより、分野は、パーソナライズされたダイナミックな治療戦略とともに、幅広いがんサブタイプの治療を提供するのに役立つ新しいアプローチを提供します。
現在、四重特異性抗体は商業的な世界市場に参入していないため、製薬会社にとって四重特異性抗体の領域を前進させる機会となっています。KuicK Researchのデータによると、製薬会社やバイオテクノロジー企業の最新の重点が標的療法の分野で揺れ動いているため、包括的な四重特異性抗体ドメインが今後5〜7年でがん疾患の治療ポートレートを近代化することは明らかです。二重特異性抗体の例は、これを確立するのに役立ちます。100社以上の競合企業が臨床の管路に参入し、最初の二重特異性抗体であるBlincytoが市場を席巻しました。同様に、四重特異性抗体の領域は、基本的に二重特異性および三重特異性抗体よりも上向きであることを考えると、同様の勝利の軌跡をたどると推定されます。
目次
Table of Content
1. Introduction to Tetraspecific Antibodies
1.1 Clinical Overview
1.2 History and Development
2. Tetraspecific Antibodies Mechanism of Action
2.1 Multispecific Formats
2.2 Tetraspecific Antibodies Bringing Immune Cells and Target Cells Closer
3. Tetraspecific Antibodies Clinical Trials Overview
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Indication
4. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase
4.1 Preclinical
4.2 Phase I
4.3 Phase I/II
4.4 Phase II
5. Current Clinical Development and Future Commercialization Outlook
5.1 Current Scenario
5.2 Future Market Commercialization Outlook
6. Tetraspecific Antibody Clinical Development Trend Analysis by Region
6.1 China
6.2 Europe
6.3 US
7. Tetraspecific Antibodies Proprietary Technologies By Company
7.1 Available Proprietary Platforms
7.2 Potential Proprietary Platforms
8. Tetraspecific Antibodies Therapeutic Application in Cancer
8.1 Solid Tumors
8.2 Hematological Disorders
9. Tetraspecific Antibodies Therapeutic Approaches
9.1 Tetraspecific Antibodies As Monotherapy
9.2 Tetraspecific Antibodies As Combinational Therapy
9.3 Tetraspecific Antibodies As Targeted Approach
10. Combination Stratagems for Tetraspecific Antibodies
11. Competitive Landscape
11.1 Innate Pharma
11.2 ModeX Therapeutics (OPKO Health)
11.3 Molecular Partners
11.4 OPKO Health
11.4 Ruijin Hospital
11.6 Sichuan Baili Pharmaceutical
11.7 SystImmune
List of Figures
Figure 1-1: FL518 - Structure
Figure 1-2: CRTB6 - Structure
Figure 1-3: LegoBody Tetraspecific Antibody Structure
Figure 1-4: LegoBody Tetra-N-Fab Post Thrombin Cleavage
Figure 2-1: Tetraspecific Antibody Structure
Figure 2-2: Tetraspecific Antibody Bringing T Cells and NK Cells In Close Proximity
Figure 3-1: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2024
Figure 3-2: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2024
Figure 3-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2024
Figure 3-4: Global - Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2024
Figure 6-1: Sichuan Biokin Pharmaceutical - Clinical Pipeline
Figure 6-2: GNC-035 Phase I Study (NCT05160545) - Initiation and Completion Year
Figure 6-3: IPH6501 Phase I/II Study (NCT06088654) - Initiation and Completion Year
Figure 6-4: ModeX Therapeutics, an OPKO Health Company Pipeline
Figure 7-1: DARPin Platform - Molecular Partners
Figure 7-2: ANKETandreg; Platform - Innate Pharma
Figure 7-3: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 7-4: STEALTH - ModeX Therapeutics
Figure 7-5: MSTAR - ModeX Therapeutics
Figure 7-6: Features of MSTAR
Figure 7-7: MATCH - Numab
Figure 7-8: Features of BiXAb
Figure 7-9: Zyngenia Technology Approach
Figure 8-1: GNC-039 Phase I Study (NCT04794972) - Initiation and Completion Year
Figure 8-2: MDX2001 Phase I/II Study (NCT06239194) - Initiation and Completion Year
Figure 8-3: GNC-038 Phase I/II Study (NCT05627856) - Initiation and Completion Year
Figure 8-4: GNC-038 Phase I/II Study (NCT05485753) - Initiation and Completion Year
Figure 8-5: GNC-035 Phase I/II Study (NCT06066203) - Initiation and Completion Year
Figure 8-6: GNC-035 Phase I/II Study (NCT06066203) - Initiation and Completion Year
Figure 8-7: Molecular Partners - MP0533
Figure 8-8: MP0533 Phase I/II Study (NCT05673057) - Initiation and Completion Year
Figure 9-1: Tetraspecific Antibody GNC035 Targeting Cell Surface Antigen CD3
Figure 9-2: Tetraspecific Antibody Engaging CD3 T cells
Figure 9-3: Tetraspecific Antibody GNC039 Targeting Co-Stimulatory Receptor 4-1BB
Figure 9-4: IPH6501 - Tetra-Specific NK Cell Engager
Figure 9-5: Tetraspecific Antibody GNC038 Targeting Immune Checkpoint Inhibitor PDL-1
Figure 9-6: Regulation of CD47 Signal From Cancer Cells By Tetraspecific Antibody
Figure 9-7: Novel Tetraspecific Format Developed By The Roche Pharma Research and Early Development
Figure 10-1: Tetraspecific Antibody Combinations
List of Tables
Table 6-1: China - Ongoing Tetraspecific Antibody Clinical Trials
Table 9-2: GNC-038- Ongoing Clinical Trial for Hematological Cancers
Table 9-1: Monotherapy Clinical Trials For Tetraspecific Antibodies
